LATEST ARTICLES

Despite Receiving Similar Treatment as White Women, Black Women have Worse Breast Cancer Outcomes

Breast cancer is the most common cancer in women in the United States and worldwide. Furthermore, hormone-receptor–positive, axillary node–negative disease accounts for approximately half of all cases of breast...

Gilteritinib Available for Prescription in the United States for Adults with Acute Myeloid Leukemia

Gilteritinib (Xospata®; Astellas Pharma) is now available for prescription in the United States for the treatment of adult patients who have relapsed or refractory (resistant to treatment) Acute Myeloid...

Lymph Node Surgery and Axillary Radiotherapy Yield Comparable 10-year Outcome in Breast Cancer

Results from the randomized, Phase III AMAROS clinical trial (NCT00014612),  presented at the San Antonio Breast Cancer Symposium (SABCS), held December 4–8, 2018, in San Antonio, Texas, shows that...

Circulating Tumor Cell Count may Help in Treatment Selection for Metastatic Breast Cancer

Results from the phase III STIC CTC clinical trial, presented at the San Antonio Breast Cancer Symposium (SABCS), held December 4–8, 2018 in San Antonio, Texas, shows that  circulating...

Study Shows Low-Dose Tamoxifen to be Safe and Effective in Reducing Recurrence + New...

Data from the randomized, Phase III TAM-01 clinical trial, presented at during the San Antonio Breast Cancer Symposium (SABCS), held December 4–8, 2018 in San Antonio, TX, shows that...

Study Shows Accelerated Partial Breast Irradiation Not Equivalent to Whole Breast Irradiation

Data presented at the San Antonio Breast Cancer Symposium (SABCS), held December 4–8, 2018 in San Antonio, TX, shows that ipsilateral breast tumor recurrence (IBTR) rates 10 years after...